Trevi Therapeutics Inc expected to post a loss of 7 cents a share - Earnings Preview

Trevi Therapeutics

10/05/2023 03:06

* Trevi Therapeutics Inc  TRVI.OQ   TRVI.O  is expected
to show no
change in quarterly revenue when it reports  results on May 11. 
    * 
    * ​Refinitiv's mean analyst estimate for Trevi Therapeutics
Inc is
for a loss of 7 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 6 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had fallen by
about 6.3%
in the last three months. ​
    * Wall Street's median 12-month price target for Trevi
Therapeutics Inc is $7.5​, above​ its last closing price
of $3.02. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2022  -0.12       -0.10      -0.06     Beat    42.9
 Sep. 30 2022  -0.13       -0.13      -0.12     Beat    11.1
 Jun. 30 2022  -0.18       -0.18      -0.14     Beat    24​
 Mar. 31 2022  -0.29       -0.29      -0.24     Beat    16.3
 ​​Dec.                    -0.30      -0.28     Beat    5.7
 31 2021                                                
 Sep. 30 2021  -0.41       -0.40      -0.34     Beat    14.5​
 Jun. 30 2021  -0.46       -0.46      -0.47     Missed  -2.6
 Mar. 31 2021  -0.54       -0.52      -0.43     Beat    17.3
 This summary was machine generated May 10 at 02:06 GMT.  All
figures in US dollars  unless otherwise stated